How Biocon's Insulin Aspart, at Centre of ‘Bribery Controversy’, is Different from Its Peers
News 18On Monday, CBI arrested top officials from the office of the country’s apex drug regulator and Bengaluru-based pharmaceutical giant Biocon Biologics among others in a case of bribery. ‘Insulin Aspart’ injection is at the center of the entire controversy as it is alleged that a bribe was given to Central Drugs Standard Control Organisation ’s official to waive off the Phase 3 clinical trial of the medicine in India. Novo Nordisk’s insulin injection Aspart has been available in India under the brand name Fiasp and Novorapid within the price range of Rs 678 to Rs 3,872. Biocon, in February 2021, had announced its own bio-similar insulin Aspart named ‘Kixelle’, which had received marketing authorisation approval from the European Commission. According to Dr Ritesh Gupta, additional director at Fortis CDOC Hospital for Diabetes and Endocrinology, “Insulin Aspart is rapid-acting insulin and its glucose-lowering action usually lasts for 4 hours.
History of this topic
)
All you need to know about Biocon's Insulin Aspart, which is at the centre of a bribery controversy
FirstpostDiscover Related
)
)
)
)
)
)
